Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Summary

This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg).

Timeline

Start

2004-05

Primary completion

—

Completion

2005-09

Drugs

Indications